Claris Lifesciences announced on Thursday that it has received approval from the Ministry of Health to market two more anti-infectives, namely Fluconazole IV 100 ml. and Levofloxacin IV 100 ml.
Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections, whereas Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections.
Claris now has another four in the pipeline for registration in Russia.
